Loading...
XNASNEO
Market cap1.90bUSD
Jan 10, Last price  
14.77USD
1D
-20.63%
1Q
9.16%
Jan 2017
72.35%
IPO
392.33%
Name

Neogenomics Inc

Chart & Performance

D1W1MN
XNAS:NEO chart
P/E
P/S
3.20
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
6.51%
Rev. gr., 5y
16.41%
Revenues
592m
+16.07%
558,0741,885,3246,475,99611,504,72520,015,31929,469,05434,371,00043,484,00059,867,00066,467,00087,069,00099,802,000244,083,000258,611,000276,741,000408,830,000444,448,000484,329,000509,728,000591,643,000
Net income
-88m
L-39.02%
-818,985-997,160-129,661-3,380,172-1,382,586-2,242,813-3,303,000-1,177,00065,0002,033,0001,132,000-2,535,000-5,723,000-846,0002,640,0008,006,0004,172,000-8,347,000-144,250,000-87,968,000
CFO
-2m
L-97.04%
-658,133-902,051-693,782-2,642,591-138,306-1,500,417-2,052,00069,000-492,0002,227,0009,450,0006,393,00021,477,00018,037,00044,786,00023,369,0001,460,000-26,723,000-65,993,000-1,953,000
Dividend
Dec 17, 20200.4 USD/sh
Earnings
Feb 18, 2025

Profile

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
IPO date
Dec 10, 2012
Employees
2,100
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
591,643
16.07%
509,728
5.24%
Cost of revenue
688,291
662,835
Unusual Expense (Income)
NOPBT
(96,648)
(153,107)
NOPBT Margin
Operating Taxes
(9,129)
(15,092)
Tax Rate
NOPAT
(87,519)
(138,015)
Net income
(87,968)
-39.02%
(144,250)
1,628.17%
Dividends
Dividend yield
Proceeds from repurchase of equity
4,624
12,587
BB yield
-0.23%
-1.10%
Debt
Debt current
11,220
6,654
Long-term debt
679,550
679,880
Deferred revenue
19
Other long-term liabilities
13,034
13,036
Net debt
275,567
248,514
Cash flow
Cash from operating activities
(1,953)
(65,993)
CAPEX
(28,752)
(30,891)
Cash from investing activities
76,707
517
Cash from financing activities
4,554
11,829
FCF
(100,430)
(129,247)
Balance
Cash
415,203
437,989
Long term investments
31
Excess cash
385,621
412,534
Stockholders' equity
(248,602)
(162,859)
Invested Capital
1,820,462
1,784,865
ROIC
ROCE
EV
Common stock shares outstanding
125,502
124,217
Price
16.18
75.11%
9.24
-72.92%
Market cap
2,030,622
76.92%
1,147,765
-71.96%
EV
2,306,189
1,396,279
EBITDA
(24,065)
(83,677)
EV/EBITDA
Interest
6,907
1,506
Interest/NOPBT